Literature DB >> 29226863

Associations between Use of Specific Analgesics and Concentrations of Amyloid-β 42 or Phospho-Tau in Regions of Human Cerebral Cortex.

Margaret E Flanagan1, Eric B Larson2,3, Rod L Walker2, C Dirk Keene4, Nadia Postupna4, Brenna Cholerton1, Joshua A Sonnen5, Sascha Dublin2,6, Paul K Crane3, Thomas J Montine1.   

Abstract

Analgesics are commonly used by older adults, raising the question of whether their use might contribute to dementia risk and neuropathologic changes of Alzheimer's disease (AD). The Adult Changes in Thought (ACT) study is a population-based study of brain aging and incident dementia among people 65 years or older who are community dwelling and not demented at entry. Amyloid-β (Aβ)42 and phospho-tau were quantified using Histelide in regions of cerebral cortex from 420 brain autopsies. Total standard daily doses of prescription opioid and non-aspirin nonsteroidal anti-inflammatory drug (NSAID) exposure during a defined 10-year exposure window were identified using automated pharmacy dispensing data and used to classify people as having no/low, intermediate, or high exposure. People with high NSAID exposure had significantly greater Aβ42 concentration in middle frontal gyrus and superior and middle temporal gyri, but not inferior parietal lobule; no Aβ42 regional concentration was associated with prescription opioid usage. People with high opioid usage had significantly greater concentration of phospho-tau in middle frontal gyrus than people with little-to-no opioid usage. Consistent with our previous studies, findings suggest that high levels of NSAID use in older individuals may promote Aβ42 accumulation in cerebral cortex.

Entities:  

Keywords:  Alzheimer’s disease; amyloid-β; neuropathology; non-steroidal anti-inflammatory drugs; opioids

Mesh:

Substances:

Year:  2018        PMID: 29226863      PMCID: PMC5745256          DOI: 10.3233/JAD-170414

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  29 in total

1.  Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI.

Authors:  J E Hixson; D T Vernier
Journal:  J Lipid Res       Date:  1990-03       Impact factor: 5.922

2.  Digital pathology and image analysis for robust high-throughput quantitative assessment of Alzheimer disease neuropathologic changes.

Authors:  Janna Hackett Neltner; Erin Lynn Abner; Frederick A Schmitt; Stephanie Kay Denison; Sonya Anderson; Ela Patel; Peter T Nelson
Journal:  J Neuropathol Exp Neurol       Date:  2012-12       Impact factor: 3.685

3.  Early effects of Aβ1-42 oligomers injection in mice: Involvement of PI3K/Akt/GSK3 and MAPK/ERK1/2 pathways.

Authors:  Fabiana Morroni; Giulia Sita; Andrea Tarozzi; Roberto Rimondini; Patrizia Hrelia
Journal:  Behav Brain Res       Date:  2016-08-03       Impact factor: 3.332

4.  Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease.

Authors:  G P Lim; F Yang; T Chu; P Chen; W Beech; B Teter; T Tran; O Ubeda; K H Ashe; S A Frautschy; G M Cole
Journal:  J Neurosci       Date:  2000-08-01       Impact factor: 6.167

5.  Cerebral cortical Aβ42 and PHF-τ in 325 consecutive brain autopsies stratified by diagnosis, location, and APOE.

Authors:  Nadia Postupna; Christopher Dirk Keene; Paul K Crane; Luis F Gonzalez-Cuyar; Joshua A Sonnen; Jessica Hewitt; Samantha Rice; Kimberly Howard; Kathleen S Montine; Eric B Larson; Thomas J Montine
Journal:  J Neuropathol Exp Neurol       Date:  2015-02       Impact factor: 3.685

6.  Adjustment for selection bias in observational studies with application to the analysis of autopsy data.

Authors:  S Haneuse; J Schildcrout; P Crane; J Sonnen; J Breitner; E Larson
Journal:  Neuroepidemiology       Date:  2009-01-29       Impact factor: 3.282

7.  Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial.

Authors:  C G Lyketsos; J C S Breitner; R C Green; B K Martin; C Meinert; S Piantadosi; M Sabbagh
Journal:  Neurology       Date:  2007-04-25       Impact factor: 9.910

8.  Glucose levels and risk of dementia.

Authors:  Paul K Crane; Rod Walker; Rebecca A Hubbard; Ge Li; David M Nathan; Hui Zheng; Sebastien Haneuse; Suzanne Craft; Thomas J Montine; Steven E Kahn; Wayne McCormick; Susan M McCurry; James D Bowen; Eric B Larson
Journal:  N Engl J Med       Date:  2013-08-08       Impact factor: 91.245

9.  Anti-inflammatory treatment in AD mice protects against neuronal pathology.

Authors:  Ji-Kyung Choi; Bruce G Jenkins; Isabel Carreras; Sukru Kaymakcalan; Kerry Cormier; Neil W Kowall; Alpaslan Dedeoglu
Journal:  Exp Neurol       Date:  2009-08-10       Impact factor: 5.330

Review 10.  Anti-inflammatory drugs and risk of Alzheimer's disease: an updated systematic review and meta-analysis.

Authors:  Jun Wang; Lan Tan; Hui-Fu Wang; Chen-Chen Tan; Xiang-Fei Meng; Chong Wang; Shao-Wen Tang; Jin-Tai Yu
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

View more
  7 in total

Review 1.  Supraphysiologic-dose anabolic-androgenic steroid use: A risk factor for dementia?

Authors:  Marc J Kaufman; Gen Kanayama; James I Hudson; Harrison G Pope
Journal:  Neurosci Biobehav Rev       Date:  2019-02-25       Impact factor: 8.989

2.  Exposure to Strong Anticholinergic Medications and Dementia-Related Neuropathology in a Community-Based Autopsy Cohort.

Authors:  Shelly L Gray; Melissa L Anderson; Joseph T Hanlon; Sascha Dublin; Rod L Walker; Rebecca A Hubbard; Onchee Yu; Thomas J Montine; Paul K Crane; Josh A Sonnen; C Dirk Keene; Eric B Larson
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

3.  Anticholinergic/sedative drug burden predicts worse memory acquisition in older racially/ethnically diverse patients with type 2 diabetes mellitus.

Authors:  Seth A Margolis; Malka Zughaft Sears; Lori A Daiello; Carly Solon; Luba Nakhutina; Claire J Hoogendoorn; Jeffrey S Gonzalez
Journal:  Int J Geriatr Psychiatry       Date:  2019-07-22       Impact factor: 3.485

4.  Alzheimer's Disease-Related Neuropathology Among Patients with Medication Treated Type 2 Diabetes in a Community-Based Autopsy Cohort.

Authors:  Douglas Barthold; Laura E Gibbons; Zachary A Marcum; Shelly L Gray; C Dirk Keene; Thomas J Grabowski; Nadia Postupna; Eric B Larson; Paul K Crane
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

Review 5.  Does Traumatic Brain Injury Cause Risky Substance Use or Substance Use Disorder?

Authors:  Christopher M Olsen; John D Corrigan
Journal:  Biol Psychiatry       Date:  2021-07-21       Impact factor: 13.382

6.  Luminex-based quantification of Alzheimer's disease neuropathologic change in formalin-fixed post-mortem human brain tissue.

Authors:  C Dirk Keene; Angela M Wilson; Mitchell D Kilgore; Lauren T Bruner; Nadia O Postupna; Martin Darvas
Journal:  Lab Invest       Date:  2018-12-20       Impact factor: 5.662

Review 7.  Chronic traumatic encephalopathy neuropathology might not be inexorably progressive or unique to repetitive neurotrauma.

Authors:  Grant L Iverson; Andrew J Gardner; Sandy R Shultz; Gary S Solomon; Paul McCrory; Ross Zafonte; George Perry; Lili-Naz Hazrati; C Dirk Keene; Rudolph J Castellani
Journal:  Brain       Date:  2019-12-01       Impact factor: 13.501

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.